Fear acquisition and extinction mechanisms in relation to treatment outcome: a study in patients with anxiety disorders

Completed

Conditions: Anxiety disorder
10002861

Registration Number: NL-OMON39222

Lead Sponsor: niversiteit Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 310

Inclusion Criteria

a. Patients with a lifetime diagnosis of the following disorders as a primary diagnosis: Panic disorder with or without agoraphobia, social anxiety disorder, specific phobia, generalized anxiety disorder, post-traumatic stress disorder and obsessive compulsive disorder.
b. Males and females between 18 and 65 years old.
c. Command of the Dutch language (i.e. ability to understand procedures and questionnaires).
d. Normal or corrected normal vision.;The inclusion criteria for the healthy controls participating in conditioning task 1 are the same as described above, with the exception of criterium a.

Exclusion Criteria

a. Current comorbid severe psychiatric disorder in the past 6 months: i.e. severe major depressive disorder (BDI * 30), bipolar disorder, psychotic disorder.
b. Lifetime history of substance dependence, or substance abuse within the last three months.
c. Mental retardation (IQ < 80)
d. History of any physical disease which may confound the results of the study according to the investigator, like brain damage.
e. Hearing/ vision problems
f. Current use of antipsychotic medication;The inclusion criteria for the healthy controls participating in conditioning task 1 are the same as described above.

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary endpoint measures of change indices are: State Trait Anxiety Inventory<br /><br>(state subscale) and Disorder specific ratings. Physiological (skin conductance<br /><br>response and electromyograhy) and self-reported (Visual analogue scales)<br /><br>measures are used to measure speed of fear acquisition, fear extinction and<br /><br>context learning. Various polymorphisms will be genotyped: serotonine (5HTTLPR,<br /><br>5-HTR1A), dopamine (COMT Val158Met, DAT), cannabinoïd (CB1 rs2180619 en CB1<br /><br>rs1049353) and glutamergic polymorfisms (SLC1A1/EAAC1 rs3780412, rs301430).<br /><br>Promising newly detected polymorphisms available through the literature will be<br /><br>tested as well. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary objectives: several questionnaires and neuropsychological tests (see<br /><br>section 3.8 and 4.4 of the research protocol) were added to be able to control<br /><br>for possible modulating effects on fear conditioning, such as: depresion,<br /><br>memory function and life-events. </p><br>